.

Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Teva
Chinese Patent Office
Chubb
Boehringer Ingelheim
US Army
Baxter
Argus Health
Cipla
Novartis
Colorcon

Generated: September 24, 2017

DrugPatentWatch Database Preview

Genzyme Company Profile

« Back to Dashboard

What is the competitive landscape for GENZYME, and when can generic versions of GENZYME drugs launch?

GENZYME has fifteen approved drugs.

There are twelve US patents protecting GENZYME drugs.

There are two hundred and seventy-six patent family members on GENZYME drugs in forty-six countries.

Summary for Applicant: Genzyme

Patents:12
Tradenames:12
Ingredients:12
NDAs:15
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Genzyme Corp
CERDELGA
eliglustat tartrate
CAPSULE;ORAL205494-001Aug 19, 2014RXYesYes► Subscribe► Subscribe► Subscribe
Genzyme
RENVELA
sevelamer carbonate
TABLET;ORAL022127-001Oct 19, 2007ABRXYesYes► Subscribe► SubscribeY ► Subscribe
Genzyme Corp
HECTOROL
doxercalciferol
CAPSULE;ORAL020862-001Jun 9, 1999ABRXYesYes► Subscribe► Subscribe► Subscribe
Genzyme Corp
CERDELGA
eliglustat tartrate
CAPSULE;ORAL205494-001Aug 19, 2014RXYesYes► Subscribe► Subscribe ► Subscribe
Genzyme Corp
CERDELGA
eliglustat tartrate
CAPSULE;ORAL205494-001Aug 19, 2014RXYesYes► Subscribe► Subscribe ► Subscribe
Genzyme
LEUPROLIDE ACETATE
leuprolide acetate
INJECTABLE;INJECTION075721-001Nov 29, 2001DISCNNoNo► Subscribe► Subscribe► Subscribe
Genzyme
RENAGEL
sevelamer hydrochloride
TABLET;ORAL021179-002Jul 12, 2000RXYesYes► Subscribe► SubscribeY ► Subscribe
Genzyme Corp
CERDELGA
eliglustat tartrate
CAPSULE;ORAL205494-001Aug 19, 2014RXYesYes► Subscribe► Subscribe► Subscribe
Genzyme
CEREZYME
imiglucerase
INJECTABLE;INJECTION020367-001May 23, 1994RXYesNo► Subscribe► Subscribe► Subscribe
Genzyme
MOZOBIL
plerixafor
SOLUTION;SUBCUTANEOUS022311-001Dec 15, 2008RXYesYes► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Genzyme

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Genzyme
RENAGEL
sevelamer hydrochloride
TABLET;ORAL021179-001Jul 12, 2000► Subscribe► Subscribe
Genzyme
RENAGEL
sevelamer hydrochloride
TABLET;ORAL021179-001Jul 12, 2000► Subscribe► Subscribe
Genzyme
RENVELA
sevelamer carbonate
FOR SUSPENSION;ORAL022318-001Aug 12, 2009► Subscribe► Subscribe
Genzyme Corp
HECTOROL
doxercalciferol
INJECTABLE;INJECTION021027-001Apr 6, 2000► Subscribe► Subscribe
Genzyme
RENAGEL
sevelamer hydrochloride
TABLET;ORAL021179-002Jul 12, 2000► Subscribe► Subscribe
Genzyme
RENAGEL
sevelamer hydrochloride
CAPSULE;ORAL020926-001Oct 30, 1998► Subscribe► Subscribe
Genzyme
RENVELA
sevelamer carbonate
FOR SUSPENSION;ORAL022318-001Aug 12, 2009► Subscribe► Subscribe
Genzyme Corp
HECTOROL
doxercalciferol
INJECTABLE;INJECTION021027-002Apr 6, 2000► Subscribe► Subscribe
Genzyme
THYROGEN
thyrotropin alfa
INJECTABLE;INJECTION020898-001Nov 30, 1998► Subscribe► Subscribe
Genzyme
RENVELA
sevelamer carbonate
TABLET;ORAL022127-001Oct 19, 2007► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for GENZYME drugs

Drugname Dosage Strength Tradename Submissiondate
plerixafor
Injection24 mg/1.2 mL vials (20 mg/mL)
MOZOBIL
12/17/2012
clofarabine
Injection1 mg/mL, 20 mL vial
CLOLAR
2/23/2012
doxercalciferol
Injection2 mcg/mL, 1 mL in 2 mL vial
HECTOROL
12/28/2011
doxercalciferol
Capsules1 mcg
HECTOROL
2/12/2010
sevelamer carbonate
Powder for Oral Suspension0.8 g/packet and 2.4 g/packet
RENVELA
12/30/2009
doxercalciferol
Capsules0.5 mcg and 2.5 mcg
HECTOROL
3/25/2009
sevelamer carbonate
Tablets800 mg
RENVELA
12/4/2008
sevelamer hydrochloride
Tablets400 mg and 800 mg
RENAGEL
5/22/2008
doxercalciferol
Injection2 mcg/mL, 2 mL ampules
HECTOROL
10/15/2007

Non-Orange Book Patents for Genzyme

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,255,336 Amino ceramide-like compounds and therapeutic methods of use► Subscribe
7,265,228Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors► Subscribe
6,569,889 Amino ceramide-like compounds and therapeutic methods of use► Subscribe
6,897,210 Quinazoline derivatives and pharmaceutical compositions containing them► Subscribe
7,935,692Methods to mobilize progenitor/stem cells► Subscribe
8,808,738Aliphatic amine polymer salts for tableting► Subscribe
5,034,518 2-fluoro-9-(2-deoxy-2-fluoro-.beta.-D-arabinofuranosyl) adenine nucleosides► Subscribe
5,916,911 Amino ceramide--like compounds and therapeutic methods of use► Subscribe
7,763,738Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors► Subscribe
8,779,163Synthesis of UDP-Glucose: N-acylsphingosine glucosyl transferase inhibitors► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Genzyme Drugs

Country Document Number Estimated Expiration
Brazil0012318► Subscribe
European Patent Office1223166► Subscribe
Poland173643► Subscribe
Australia2006292672► Subscribe
South Africa200609110► Subscribe
European Patent Office1807057► Subscribe
Czech Republic20021344► Subscribe
World Intellectual Property Organization (WIPO)2005112934► Subscribe
Denmark1411918► Subscribe
Czech Republic9901039► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Genzyme Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
90029-3Sweden► SubscribePRODUCT NAME: ELIGLUSTAT, VALFRITT I FORM AV ETT FYSIOLOGISKT GODTAGBART SALT; REG. NO/DATE: EU/1/14/974 20150121
C/GB02/011United Kingdom► SubscribePRODUCT NAME: SEVELAMER; REGISTERED: UK EU/1/99/120/001-004 20000202
C0038France► SubscribePRODUCT NAME: CLOFARABINE; REGISTRATION NO/DATE IN FRANCE: EU/1/06/334/001 DU 20060529; REGISTRATION NO/DATE AT EEC: EU/1/06/334/001 DU 20060529
4 4-2015Slovakia► SubscribePRODUCT NAME: ELIGLUSTAT (VO FORME TARTRATU); REGISTRATION NO/DATE: EU/1/14/974 20150121
C/GB12/031United Kingdom► SubscribePRODUCT NAME: PLERIXAFOR OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR METAL COMPLEX THEREOF; REGISTERED: UK EU/1/09/537/001 20090804
717Luxembourg► SubscribePRODUCT NAME: ELIGLUSTAT, EVENTUELLEMENT SOUS LA FORME D UN SEL PHYSIOLOGIQUEMENT ACCEPTABLE. FIRST REGISTRATION: 20150121
0716606/01Switzerland► SubscribePRODUCT NAME: SEVELAMER; REGISTRATION NUMBER/DATE: SWISSMEDIC 56297 10.02.2004
C/GB10/004United Kingdom► SubscribePRODUCT NAME: PLERIXAFOR IN ALL FORMS PROTECTED BY THE BASIC PATENT; REGISTERED: UK EU/1/09/537/001 20090731; REASON FOR LAPSE: SURRENDERED
0150027 00161Estonia► SubscribePRODUCT NAME: ELIGLUSTAAT;REG NO/DATE: EU/1/14/974 21.01.2015
2009 00052Denmark► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Express Scripts
Healthtrust
US Department of Justice
Teva
McKesson
Chinese Patent Office
Cantor Fitzgerald
Merck
Argus Health
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot